TB Vaccine Study Maps Antibodies Linked to Protection, Offering New Clues for Future Shots

November 16, 2026
TB Vaccine Study Maps Antibodies Linked to Protection, Offering New Clues for Future Shots
  • Tuberculosis kills more than 1.2 million people each year, but vaccine development has been slowed by the bacterium’s ability to evade immune defenses and by limited understanding of what protective immunity looks like.

  • The only licensed TB vaccine, BCG, is more than a century old and protects children from severe disease, but its effectiveness in adults is inconsistent; the M72 candidate is now in a 20,000-person Phase 3 trial, with results expected in late 2028.

  • To help close the knowledge gap, Mehak Khan and her team used machine learning and protein microarrays to map antibody responses across roughly 4,000 Mycobacterium tuberculosis proteins, studying people with active or latent TB, heavily exposed people who resisted infection, and rhesus macaques given BCG through different routes.

  • Unlike earlier research focused mainly on people with active disease, the atlas compared groups that appeared to control the bacterium, enabling researchers to identify proteins repeatedly recognized in association with protection.

  • Several proteins used in experimental vaccines, including M72, drew little antibody recognition in these groups, while another set of bacterial proteins was consistently recognized; antibodies from some protected groups also helped immune cells recognize and engulf targets more effectively.

  • The findings suggest antibodies may contribute to protection, but they do not show that antibodies cause it: the responses could instead reflect effective T-cell immunity, and the newly identified antigens still need to be tested for protective effects.

  • TB vaccine research remains unusually difficult because there is no reliable correlate of protection, no animal model that consistently predicts efficacy in humans, and trials are costly; philanthropy is funding the estimated $550 million M72 trial in full.

  • The challenge matters especially because TB is strongly linked to poverty, and prevention also relies on nutrition, healthcare, screening and long antibiotic courses—services that can be difficult to provide.

  • Researchers describe the atlas as an early step, not an immediate solution, and say it does not mean M72 will fail; future vaccines may combine antigens that trigger both T-cell and antibody responses.

Summary based on 1 source


Get a daily email with more Science stories

More Stories